The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer

Linehan, 2004, Genetic basis of cancer of the kidney: disease-specific approaches to therapy, Clin Cancer Res, 10, 6282S, 10.1158/1078-0432.CCR-050013 Kaelin, 2005, The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing, Cold Spring Harb Symp Quant Biol, 70, 159, 10.1101/sqb.2005.70.001 Niu, 2012, The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C, Oncogene, 31, 776, 10.1038/onc.2011.266 Zhang, 2013, The contributions of HIF-target genes to tumor growth in RCC, PLoS One, 8, e80544, 10.1371/journal.pone.0080544 Yang, 2007, pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2, Mol Cell, 28, 15, 10.1016/j.molcel.2007.09.010 Zhang, 2012, The roles of VHL-dependent ubiquitination in signaling and cancer, Front Oncol, 2, 35, 10.3389/fonc.2012.00035 Zhou, 2011, The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR, PLoS One, 6, e23936, 10.1371/journal.pone.0023936 Iliopoulos, 1995, Tumour suppression by the human von Hippel-Lindau gene product, Nat Med, 1, 822, 10.1038/nm0895-822 Kondo, 2002, Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein, Cancer Cell, 1, 237, 10.1016/S1535-6108(02)00043-0 Maranchie, 2002, The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma, Cancer Cell, 1, 247, 10.1016/S1535-6108(02)00044-2 Kondo, 2003, Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth, PLoS Biol, 1, E83, 10.1371/journal.pbio.0000083 Zimmer, 2004, Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL−/− tumors, Mol Cancer Res, 2, 89, 10.1158/1541-7786.89.2.2 Rini, 2009, Resistance to targeted therapy in renal-cell carcinoma, Lancet Oncol, 10, 992, 10.1016/S1470-2045(09)70240-2 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Vogelstein, 2013, Cancer genome landscapes, Science, 339, 1546, 10.1126/science.1235122 Varela, 2011, Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma, Nature, 469, 539, 10.1038/nature09639 2013, Comprehensive molecular characterization of clear cell renal cell carcinoma, Nature, 499, 43, 10.1038/nature12222 Davis, 2014, The somatic genomic landscape of chromophobe renal cell carcinoma, Cancer Cell, 26, 319, 10.1016/j.ccr.2014.07.014 2014, Comprehensive molecular characterization of urothelial bladder carcinoma, Nature, 507, 315, 10.1038/nature12965 Barbieri, 2012, Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer, Nat Genet, 44, 685, 10.1038/ng.2279 Grasso, 2012, The mutational landscape of lethal castration-resistant prostate cancer, Nature, 487, 239, 10.1038/nature11125 Dalgliesh, 2010, Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes, Nature, 463, 360, 10.1038/nature08672 Guo, 2012, Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma, Nat Genet, 44, 17, 10.1038/ng.1014 Peña-Llopis, 2012, BAP1 loss defines a new class of renal cell carcinoma, Nat Genet, 44, 751, 10.1038/ng.2323 Sato, 2013, Integrated molecular analysis of clear-cell renal cell carcinoma, Nat Genet, 45, 860, 10.1038/ng.2699 Gerlinger, 2012, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing, N Engl J Med, 366, 883, 10.1056/NEJMoa1113205 Gerlinger, 2014, Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing, Nat Genet, 46, 225, 10.1038/ng.2891 Sankin, 2014, The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling, Cancer Med, 3, 1485, 10.1002/cam4.293 Kapur, 2013, Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation, Lancet Oncol, 14, 159, 10.1016/S1470-2045(12)70584-3 Hakimi, 2013, Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network, Clin Cancer Res, 19, 3259, 10.1158/1078-0432.CCR-12-3886 Hakimi, 2013, Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma, Eur Urol, 63, 848, 10.1016/j.eururo.2012.09.005 Pawlowski, 2013, Loss of PBRM1 expression is associated with renal cell carcinoma progression, Int J Cancer, 132, E11, 10.1002/ijc.27822 da Costa, 2014, Polybromo-1 (PBRM1), a SWI/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma, BJU Int, 113, E157, 10.1111/bju.12426 Nagl, 2005, The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest, Cancer Res, 65, 9236, 10.1158/0008-5472.CAN-05-1225 Lichner, 2013, The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma, Am J Pathol, 182, 1163, 10.1016/j.ajpath.2013.01.007 Xue, 2000, The human SWI/SNF-B chromatin-remodeling complex is related to yeast rsc and localizes at kinetochores of mitotic chromosomes, Proc Natl Acad Sci U S A, 97, 13015, 10.1073/pnas.240208597 Yan, 2005, PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes, Genes Dev, 19, 1662, 10.1101/gad.1323805 Wang, 2004, Polybromo protein BAF180 functions in mammalian cardiac chamber maturation, Genes Dev, 18, 3106, 10.1101/gad.1238104 Huang, 2008, Coronary development is regulated by ATP-dependent SWI/SNF chromatin remodeling component BAF180, Dev Biol, 319, 258, 10.1016/j.ydbio.2008.04.020 Wurster, 2012, IL-10 transcription is negatively regulated by BAF180, a component of the SWI/SNF chromatin remodeling enzyme, BMC Immunol, 13, 9, 10.1186/1471-2172-13-9 Xia, 2008, BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer, Cancer Res, 68, 1667, 10.1158/0008-5472.CAN-07-5276 Burrows, 2010, Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence, Proc Natl Acad Sci U S A, 107, 14280, 10.1073/pnas.1009559107 Brownlee, 2014, BAF180 promotes cohesion and prevents genome instability and aneuploidy, Cell Rep, 6, 973, 10.1016/j.celrep.2014.02.012 Kakarougkas, 2014, Requirement for PBAF in transcriptional repression and repair at DNA breaks in actively transcribed regions of chromatin, Mol Cell, 55, 723, 10.1016/j.molcel.2014.06.028 Duns, 2010, Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma, Cancer Res, 70, 4287, 10.1158/0008-5472.CAN-10-0120 van Haaften, 2009, Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer, Nat Genet, 41, 521, 10.1038/ng.349 Zeng, 2002, Bromodomain: an acetyl-lysine binding domain, FEBS Lett, 513, 124, 10.1016/S0014-5793(01)03309-9 Thompson, 2009, Polybromo-1: the chromatin targeting subunit of the PBAF complex, Biochimie, 91, 309, 10.1016/j.biochi.2008.10.019 Chandrasekaran, 2007, Polybromo-1-bromodomains bind histone H3 at specific acetyl-lysine positions, Biochem Biophys Res Commun, 355, 661, 10.1016/j.bbrc.2007.01.193 Charlop-Powers, 2010, Structural insights into selective histone H3 recognition by the human polybromo bromodomain 2, Cell Res, 20, 529, 10.1038/cr.2010.43 Jensen, 1998, BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression, Oncogene, 16, 1097, 10.1038/sj.onc.1201861 Nishikawa, 2009, BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity, Cancer Res, 69, 111, 10.1158/0008-5472.CAN-08-3355 Harbour, 2010, Frequent mutation of BAP1 in metastasizing uveal melanomas, Science, 330, 1410, 10.1126/science.1194472 Bott, 2011, The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma, Nat Genet, 43, 668, 10.1038/ng.855 Testa, 2011, Germline BAP1 mutations predispose to malignant mesothelioma, Nat Genet, 43, 1022, 10.1038/ng.912 Wiesner, 2011, Germline mutations in BAP1 predispose to melanocytic tumors, Nat Genet, 43, 1018, 10.1038/ng.910 Carbone, 2013, BAP1 and cancer, Nat Rev Cancer, 13, 153, 10.1038/nrc3459 Popova, 2013, Germline BAP1 mutations predispose to renal cell carcinomas, Am J Hum Genet, 92, 974, 10.1016/j.ajhg.2013.04.012 Farley, 2013, A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma, Mol Cancer Res, 11, 1061, 10.1158/1541-7786.MCR-13-0111 Abdel-Rahman, 2011, Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers, J Med Genet, 48, 856, 10.1136/jmedgenet-2011-100156 Wadt, 2012, A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma, Pigment Cell Melanoma Res, 25, 815, 10.1111/pcmr.12006 Cheung, 2013, Further evidence for germline BAP1 mutations predisposing to melanoma and malignant mesothelioma, Cancer Genet, 206, 206, 10.1016/j.cancergen.2013.05.018 Pilarski, 2014, Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting three new cases, Genes Chromosomes Cancer, 53, 177, 10.1002/gcc.22129 Dey, 2012, Loss of the tumor suppressor BAP1 causes myeloid transformation, Science, 337, 1541, 10.1126/science.1221711 Xu, 2014, Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma, Cancer Res, 74, 4388, 10.1158/0008-5472.CAN-14-1328 Scheuermann, 2010, Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB, Nature, 465, 243, 10.1038/nature08966 Eletr, 2011, An emerging model for BAP1's role in regulating cell cycle progression, Cell Biochem Biophys, 60, 3, 10.1007/s12013-011-9184-6 Machida, 2009, The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1, J Biol Chem, 284, 34179, 10.1074/jbc.M109.046755 Sowa, 2009, Defining the human deubiquitinating enzyme interaction landscape, Cell, 138, 389, 10.1016/j.cell.2009.04.042 Yu, 2010, The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression, Mol Cell Biol, 30, 5071, 10.1128/MCB.00396-10 Ismail, 2014, Germline mutations in BAP1 impair its function in DNA double-strand break repair, Cancer Res, 74, 4282, 10.1158/0008-5472.CAN-13-3109 Joseph, 2014, Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma, Cancer, 120, 1059, 10.1002/cncr.28521 Gossage, 2014, Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma, Genes Chromosomes Cancer, 53, 38, 10.1002/gcc.22116 Brugarolas, 2013, PBRM1 and BAP1 as novel targets for renal cell carcinoma, Cancer J, 19, 324, 10.1097/PPO.0b013e3182a102d1 Pena-Llopis, 2013, Cooperation and antagonism among cancer genes: the renal cancer paradigm, Cancer Res, 73, 4173, 10.1158/0008-5472.CAN-13-0360 Wagner, 2012, Understanding the language of Lys36 methylation at histone H3, Nat Rev Mol Cell Biol, 13, 115, 10.1038/nrm3274 Buck, 2014, Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma, Oncogene, 33, 4961, 10.1038/onc.2013.455 Simon, 2014, Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects, Genome Res, 24, 241, 10.1101/gr.158253.113 Carvalho, 2014, SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint, Elife, 3, e02482, 10.7554/eLife.02482 Li, 2013, The histone mark H3K36me3 regulates human DNA mismatch repair through its interaction with MutSα, Cell, 153, 590, 10.1016/j.cell.2013.03.025 Pfister, 2014, SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability, Cell Rep, 7, 2006, 10.1016/j.celrep.2014.05.026 Barski, 2007, High-resolution profiling of histone methylations in the human genome, Cell, 129, 823, 10.1016/j.cell.2007.05.009 Vermeulen, 2007, Selective anchoring of TFIID to nucleosomes by trimethylation of histone H3 lysine 4, Cell, 131, 58, 10.1016/j.cell.2007.08.016 Benayoun, 2014, H3K4me3 breadth is linked to cell identity and transcriptional consistency, Cell, 158, 673, 10.1016/j.cell.2014.06.027 Yamaguchi, 2014, Regulation and role of EZH2 in Cancer, Cancer Res Treat, 46, 209, 10.4143/crt.2014.46.3.209